Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring EGFR mutations. Among these patients, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinno, Yuki, Goto, Yasushi, Watanabe, Sho, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267457/
https://www.ncbi.nlm.nih.gov/pubmed/30559979
http://dx.doi.org/10.1136/esmoopen-2018-000399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267457/
https://www.ncbi.nlm.nih.gov/pubmed/30559979
http://dx.doi.org/10.1136/esmoopen-2018-000399

Ejemplares similares